We develop novel small molecules that modulate mitochondrial function and rejuvenate cells.
Our lead product, MITO-66, is a reagent that improves the performance of CAR T cell therapies against cancer. Used during the ex vivo manufacturing process, MITO-66 triggers an epigenetic reprogramming and generate T cells that can persist, self-renew and provide durable stemness. MITO-66 is currently being tested by more than 10 CAR T manufacturers. Our goal is to start a clinical phase in 2024 with at least one of these players.
Beyond T cells, our small molecules have been shown to trigger the proliferation of stem cells in a variety of tissues (skin, intestine, neurons) which offers exciting perspectives in other indications.
Location: Switzerland, Geneva, Plan-les-Ouates
Total raised: $1.63M
Investors 2
| Date | Name | Website |
| 21.04.2023 | Venture Ki... | venturekic... |
| 08.07.2022 | VentureLab | venturelab... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.01.2023 | Seed | $1.63M | - |
Mentions in press and media 8
| Date | Title | Description | Source |
| 16.11.2023 | Three Geneva Startups awarded FIF Funding | The Fongit Innovation Fund (FIF) fosters innovation and the scale-up of promising companies from t... | startuptic... |
| 06.11.2023 | A decent representation at BIO-Europe | Attending events like BIO-Europe comes with several benefits for young companies. They will have t... | startuptic... |
| 19.10.2023 | Global accelerators propel Swiss life sciences | MPC Therapeutics, a biotech developing small molecules that modulate mitochondrial metabolism, has... | startuptic... |
| 05.06.2023 | A significant number of Swiss biotechs exhibit in Boston | The BIO International Convention awaits more than 14,000 biotechnology and pharma leaders in Bosto... | startuptic... |
| 11.01.2023 | MPC Therapeutics Closes CHF 1.5M Seed Funding Round | MPC Therapeutics, a Geneva, Switzerland-based biotechnology company focused on metabolism and rejuve... | finsmes.co... |
| 10.01.2023 | MPC Therapeutics raises CHF 1.5 million in a seed round to i... | MPC Tx was founded in 2018 to develop molecules able to modulate mitochondrial function and trigger ... | venturekic... |
| 10.01.2023 | CHF 1.5M for MPC Therapeutics Expanding Pipeline | MPC Therapeutics was founded in 2018 to develop molecules able to modulate mitochondrial function an... | startuptic... |
| - | MPC Therapeutics | “We develop a new generation of drugs targeting mitochondria” | fastfounde... |